Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556302 | PMC |
| http://dx.doi.org/10.1055/s-0043-1770084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022.
Can Commun Dis Rep
January 2024
Centre for Immunization Surveillance, Infectious Diseases and Vaccination Programs Branch, Public Health Agency of Canada, Ottawa, ON.
Background: Seasonal influenza vaccines (SIV) authorized for use in Canada have all undergone rigorous regulatory assessments for safety and effectiveness. Serious adverse events following immunization (AEFI) can occur, though they are rare. Continuous safety surveillance of vaccines during the post-marketing phase is a critical component of vaccination programs.
View Article and Find Full Text PDFSevere Oculorespiratory Reflex during Ophthalmic Artery Catheterization in an Infant with Retinoblastoma.
Indian J Radiol Imaging
October 2023
Department of Anaesthesiology, Sakra World Hospital, Bengaluru, Karnataka, India.
Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma.
Paediatr Anaesth
October 2013
Department of Anaesthesia, Great Ormond Street Hospital For Children NHS Foundation Trust, London, UK.
Objective: To describe our experience with superselective ophthalmic artery chemotherapy (SOAC) in retinoblastoma and to report the serious adverse cardio-respiratory reactions we have observed.
Methods: SOAC was performed using a standardized protocol for general anesthesia, ophthalmic artery catheterization, and pulsed infusion of melphalan. Adverse reactions were defined as those in which the patient required active treatment to maintain cardio-respiratory stability.
Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons.
Arch Intern Med
November 2004
Institut National de Santé Publique du Québec, Québec, Canada.
Background: Oculorespiratory syndrome (ORS) after influenza vaccination has many features of an allergic reaction.
Methods: The objective of the study was to estimate the recurrence rate of ORS after receipt of either of 2 influenza vaccines available in Canada for the 2002-2003 influenza season in individuals who experienced ORS in 2000 or 2001. We designed a randomized, crossover, double-blind, placebo-controlled trial in which patients received the vaccine and the placebo 7 days apart.
Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event?
Clin Infect Dis
March 2003
University of British Columbia Centre for Disease Control, University of British Columbia, Vancouver, Canada.
During the 2000-2001 influenza immunization campaign in Canada, a new adverse event, oculo-respiratory syndrome (ORS), was noted in association with administration of vaccine supplied by one manufacturer. The original case definition for ORS specified bilateral conjunctivitis, facial edema, or respiratory symptoms beginning 2-24 h after influenza vaccination and resolving within 48 h after onset. To characterize the spectrum, severity, and impact of ORS, we contacted persons who had reported any influenza vaccine-associated adverse event in British Columbia, Canada, during the 2000-2001 vaccination campaign.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!